SeemaAliBhatMD

Hematology • Columbus, OH

Physician

Join to view full profile

Dr. Bhat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bhat's full profile

Already have an account?

Office
460 W 10th Ave
Columbus, OH 43210
Phone+1 614-293-3196

Fax+1 614-293-4812

Summary

Dr. Seema A. Bhat is an Oncologist in Columbus, OH and is affiliated with multiple hospitals in the area, including James Cancer Hospital and Solove Research Institute and Ohio State University Wexner Medical Center. She received her medical degree from Government Medical College of Jammu and Kashmir and has been in practice for 19 years. She also speaks multiple languages, including Kashmiri, Urdu and Hindi. She specializes in hematologic/Medical oncology and is experienced in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, cold agglutinin disease, Autoimmune hemolytic anemia, Lymphomas and related disorders.

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 2008 - 2011
University at BuffaloResidency, Internal Medicine, 2004 - 2008
Government Medical College of Jammu and KashmireClass of 1999

Certifications & Licensure

OH State Medical License 2018 - 2025
NY State Medical License 2011 - 2020
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia Start of enrollment: 2012 Apr 01
Terminated
Phase 2
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Start of enrollment: 2020 Mar 24
Terminated
Phase 1, Phase 2

Publications & Presentations

PubMed

Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia.
Nilesh Kapoor, Qiuhong Zhao, Andrew Stiff, Seema A Bhat, Mirela I Anghelina
Ejhaem. 2024-10-01
1 citations
Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation.
John Alan Gambril, Sanam M Ghazi, Stephen Sansoterra, Mussammat Ferdousi, Onaopepo Kola-Kehinde
Leukemia. 2024-10-01
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia.
Janani Ravikrishnan, Daisy Y Diaz-Rohena, Elizabeth Muhowski, Xiaokui Mo, Tzung-Huei Lai
Haematologica. 2024-08-08

Abstracts/Posters

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations
Seema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
Seema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity
Seema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia
Seema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
Seema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy
Seema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study
Seema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL
Seema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia
Seema A. Bhat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all